The effect of ellagic acid on platelet activation as measured by the quantification of P-selectin using flow cytometry

AANA Journal

Volumn 78, Issue 6, 2010, Pages 453-459

  Attilio, Peter ^a   Merritt, Corey ^b   Sims, Janet ^c   Kane, Nancy ^d   O'Sullivan, Joseph ^e  

^a WILLIAM BEAUMONT ARMY MEDICAL CENTER   (United States)

^b MARTIN ARMY COMMUNITY HOSPITAL   (United States)

^c MADIGAN ARMY MEDICAL CENTER   (United States)

^d Ireland Army Community Hospital   (United States)

^e US Army Medical Department Center & School   (United States)

Author keywords

COX inhibitors; Ellagic acid; Flow cytometry; Platelets; Sprague Dawley rats

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ELLAGIC ACID; KETOROLAC; MELOXICAM; PADGEM PROTEIN;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; MALE; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; THROMBOCYTE ACTIVATION;

ANESTHESIA; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DIETARY SUPPLEMENTS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; ELLAGIC ACID; FLOW CYTOMETRY; HEMORRHAGE; HERB-DRUG INTERACTIONS; KETOROLAC; MALE; P-SELECTIN; PHYTOTHERAPY; PLATELET ACTIVATION; RATS; RATS, SPRAGUE-DAWLEY; THIAZINES; THIAZOLES;

EID: 78650490633     PISSN: 00946354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kaye AD, Clarke RC, Sabar R, et al. Herbal medicines: current trends in anesthesiology practice-a hospital survey. J Clin Anesth. 2000; 12(6):468-471.
2. Marinac JS, Buchinger CL, Godfrey LA, Wooten JM, Sun C, Willsie SK. Herbal products and dietary supplements: a survey of use, attitudes and knowledge among older adults. J Am Osteopath Assoc. 2007;107(1):13-20.
3. Messina BA. Herbal supplements: Facts and myths-talking to your patients about herbal supplements. J Perianesth Nurs. 2006;21(4): 268-278.
4. Temple MD, Fagerlund K, Saewyc E. A national survey of certified registered nurse anesthetists' knowledge, beliefs, and assessment of herbal supplements in the anesthesia setting. AANA J. 2005;73(5): 368-377.
5. Crowe S, Lyons B. Herbal medicine use by children presenting for ambulatory anesthesia and surgery. Paediatr Anaesth. 2004;14(11):916-919.
6. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med. 2005;11(1):42-49.
7. Hannum SM. Potential impact of strawberries on human health: a review of the science. Crit Rev Food Sci Nutr. 2004;44(1):1-17.
8. Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem. 2006;54(3):980-985.
9. Rangkadilok N, Sitthimonchai S, Worasuttayangkurn L, Mahidol C, Ruchirawat M, Satayavivad J. Evaluation of free radical scavenging and antityrosinase activities of standardized longan fruit extract. Food Chem Toxicol. 2007;45(2):328-336.
10. Ratnoff OD, Crum JD. Activation of Hageman factor by solutions of ellagic acid. J Lab Clin Med. 1964;63:359-377.
11. Afaq F, Malik A, Syed D, Maes D, Matsui MS, Mukhtar H. Pomegranate fruit extract modulates UV-B-mediated phosphorylation of mitogen-activated protein kinases and activation of nuclear factor kappa B in normal human epidermal keratinocytes. Photochem Photobiol. 2005; 81(1):38-45.
12. Smyth E, Burke A, Fitzgerald GA. Lipid-derived autocoids: eicosanoids and platelet-activating factor. In: Brunton LL, Laso JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006:653-670.
13. Gerhäuser C, Klimo K, Heiss E, et al. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res. 2003;523-524:163-172.
14. Zhang Y, DeWitt DL, Murugesan S, Nair MG. Novel lipid-peroxidation-and cyclooxygenase-inhibitory tannins from Picrorhiza kurroa seeds. Chem Biodivers. 2004;1(3):426-441.
15. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10): 1397-1421.
16. Rogerio AP, Fontanari C, Melo MC, et al. Anti-inflammatory, analgesic and anti-oedematous effects of Lafoensia pacari extract and ellagic acid. J Pharm Pharmacol. 2006;58(9):1265-1273.
17. Narayanan BA, Narayanan NK, Stoner GD, Bullock BP. Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci. 2002;70(15):1821-1839.
18. Boukharta M, Jalbert G, Castonguay A. Biodistribution of ellagic acid and dose-related inhibition of lung tumorigenesis in A/J mice. Nutr Cancer. 1992;18(2):181-189.
19. Narayanan BA, Geoffroy O, Willingham MC, Re GG, Nixon DW. p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett. 1999; 136(2):215-221.
20. Lin SS, Hung CF, Ho CC, Liu YH, Ho HC, Chung JG. Effects of ellagic acid by oral administration on N-acetylation and metabolism of 2-aminofluorene in rat brain tissues. Neurochem Res. 2000;25(11): 1503-1508.
21. Perchellet EM, Sperfslage BJ, Qabaja G, Jones GB, Perchellet JP. Quinone isomers of the WS-5995 antibiotics: synthetic antitumor agents that inhibit macromolecule synthesis, block nucleoside transport, induce DNA fragmentation, and decrease the growth and viability of L1210 leukemic cells more effectively than ellagic acid and genistein in vitro. Anticancer Drugs. 2001;12(5):401-417.
22. Botti RE, Ratnoff OD. Studies on the pathogenesis of thrombosis: an experimental "hypercoagulable" state induced by the intravenous injection of ellagic acid. J Lab Clin Med. 1964;64:385-398.
23. Girolami A, Agostino D, Cliffton EE. The effect of ellagic acid on coagulation in vivo. Blood. 1966;27(1):93-102.
24. Cliffton EE, Girolami A, Agostino D. The effect of ellagic acid on the thrombin-induced hemorrhagic syndrome in the rat. Blood. 1966;28 (2):253-257.
25. Cliffton EE. The effects of ellagic acid on the coagulation mechanisms and on traumatic bleeding. Am J Med Sci. 1967;254(4):483-490.
26. Damas J, Remacle-Volon G. The thrombopenic effect of ellagic acid in the rat: another model of platelet stimulation "in vivo." Thromb Res. 1987;45(2):153-163.
27. Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circulation. 2005;112(17):2725-2734.
28. Breen P. Basics of coagulation pathways. Int Anesthesiol Clin. 2004;42 (3):1-9.
29. Moritz A, Walcheck BK, Weiss DJ. Flow cytometric detection of activated platelets in the dog. Vet Clin Pathol. 2003;32(1):6-12.
30. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood. 1996;87(12):4925-4936.
31. Ellagic Insurance Formula. Greenwood Health Systems. Website. http://www.greenwoodhealth.net/np/1_eif.htm. Accessed October 16, 2010.
32. Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther. 1997;283(3): 1069-1075.
33. Randolph BC, Peters MA. Analgesic effectiveness of ketorolac compared to meperidine in the rat formalin test. Anesth Prog. 1997;44(1):11-16.
34. Churchill L, Graham AG, Shih CK, Puletti D, Farina PR, Gob PM. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology. 1996;4:125-135.
35. Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol. 1996;51(1):29-38.
36. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Bolting J, Sotting R. Improved Non-Steroidal Anti-inflammatory Drugs: COX-2 Enzyme Inhibitors. Dordrecht, Netherlands: Kluwer Academic Publishers; 1996:103-119.